<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Measles, mumps, and rubella immunization in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Measles, mumps, and rubella immunization in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Measles, mumps, and rubella immunization in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia L Hibberd, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The combination measles, mumps, and rubella (MMR) vaccine includes live virus vaccines against measles, mumps, and rubella; it is an important tool for preventing serious illness due to these infections [<a href="#rid1">1,2</a>].</p><p>Issues related to the use of combination MMR vaccine in adults will be discussed here; use of MMR immunization in infants, children, and adolescents is discussed separately. (See  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents"</a> and  <a class="medical medical_review" href="/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a>.)</p><p>Issues related to the epidemiology, clinical manifestations, diagnosis, and management of measles, mumps, and rubella are discussed separately. (See  <a class="medical medical_review" href="/d/html/3021.html" rel="external">"Measles: Clinical manifestations, diagnosis, treatment, and prevention"</a> and  <a class="medical medical_review" href="/d/html/8310.html" rel="external">"Mumps"</a> and  <a class="medical medical_review" href="/d/html/8301.html" rel="external">"Rubella"</a>.)</p><p class="headingAnchor" id="H26466089"><span class="h1">MEASLES, MUMPS, AND RUBELLA INFECTIONS</span><span class="headingEndMark"> — </span>The measles virus causes an acute infection characterized by fever, cough, coryza, conjunctivitis, rash  (<a class="graphic graphic_picture graphicRef57093 graphicRef57803" href="/d/graphic/57093.html" rel="external">picture 1A-B</a>), and enanthem  (<a class="graphic graphic_picture graphicRef57571" href="/d/graphic/57571.html" rel="external">picture 2</a>) that may be followed by severe complications including encephalitis. Adults with measles are at increased risk of mortality compared with older children, and measles in pregnancy is associated with premature labor and spontaneous abortion [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/3021.html" rel="external">"Measles: Clinical manifestations, diagnosis, treatment, and prevention"</a>.)</p><p>The mumps virus causes an acute infection characterized by parotid swelling  (<a class="graphic graphic_picture graphicRef53503" href="/d/graphic/53503.html" rel="external">picture 3</a>). Mumps infection usually is self-limited but may be associated with complications including orchitis and oophoritis, aseptic meningitis, and encephalitis. The most serious complications of mumps arise more frequently in adults than in children, including neurologic complications. (See  <a class="medical medical_review" href="/d/html/8310.html" rel="external">"Mumps", section on 'Clinical manifestations'</a>.)</p><p>The rubella virus causes a generally mild acute infection with a characteristic rash  (<a class="graphic graphic_picture graphicRef61263" href="/d/graphic/61263.html" rel="external">picture 4</a>) that can affect both children and adults. Fetal rubella infection can cause significant congenital anomaly; immunity among adults (particularly women of childbearing age) is essential for elimination of the most important consequences of rubella: congenital rubella syndrome, miscarriage, and fetal death. (See  <a class="medical medical_review" href="/d/html/8301.html" rel="external">"Rubella", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy"</a> and  <a class="medical medical_review" href="/d/html/6047.html" rel="external">"Congenital rubella", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H8597320"><span class="h1">VACCINE EFFICACY</span><span class="headingEndMark"> — </span>Routine measles, mumps, and rubella (MMR) immunization is effective in preventing measles, mumps, and rubella infection as indicated by the dramatic decline in the number of cases of measles, mumps, and rubella following the introduction of vaccine programs in the 1960s  (<a class="graphic graphic_figure graphicRef101586 graphicRef101590 graphicRef70446" href="/d/graphic/101586.html" rel="external">figure 1A-C</a>) [<a href="#rid1">1,4</a>]. It is rare for immunocompetent individuals to not be fully immune after two doses of MMR  (<a class="graphic graphic_table graphicRef64771" href="/d/graphic/64771.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Measles – Measles vaccination usually leads to long-term immunity. In the United States, measles antibodies develop in 96 percent of individuals vaccinated at age 12 months and in 98 percent of individuals vaccinated at age 15 months [<a href="#rid3">3,5</a>]. For the small percentage of nonresponders to the first vaccine dose, a second dose will result in seroconversion in 90 percent of cases [<a href="#rid6">6</a>], resulting in 99 percent immunity among individuals who have received two doses of measles vaccine [<a href="#rid7">7</a>]. Thus, the second vaccine dose generally provides immunity among nonresponders to the first dose. There are no compelling data to support a routine third dose of MMR vaccine for the prevention of measles [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Measles antibody titers have been shown to decrease over time [<a href="#rid9">9-12</a>]. Most people with waning antibody titers after vaccination have an anamnestic response to revaccination, suggesting continued immunity [<a href="#rid13">13</a>]. However, measles can occur in previously vaccinated individuals. As an example, in one study including 232 cases of measles in California between 2000 and 2015, 13 individuals (11 percent) had received ≥2 doses of measles vaccine [<a href="#rid14">14</a>]. These individuals had milder disease. At least one analysis has suggested that waning immunity contributes to lower vaccine efficacy [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1">The evidence for efficacy of MMR vaccine administered as post-exposure prophylaxis for prevention of measles is limited and mixed [<a href="#rid16">16-18</a>]. Prophylactic post-exposure vaccination may provide some protection in settings of limited contact such as schools and daycare centers [<a href="#rid1">1</a>]. The efficacy is likely to be diminished in household settings with intense contact because, in these settings, individuals are exposed for prolonged duration during the prodromal period when the index patient is infectious.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mumps – Mumps vaccination seroconversion rates range from 84 to 100 percent [<a href="#rid19">19</a>]. In one study comparing the persistence of cellular and humoral immunity to mumps virus in 50 individuals who had follow-up more than 20 years after receiving two MMR vaccinations during early childhood with a control group who had a history of naturally acquired immunity to mumps, levels of detectable anti-mumps virus immunoglobulin (Ig)G antibodies were lower in the vaccinated group [<a href="#rid20">20</a>]. However, mumps antigen-specific lymphoproliferative responses were detected in 98 percent of all subjects, consistent with long persistence of cellular immunity. Other studies have noted that cellular immune responses to the mumps virus can be identified in the majority of vaccinated individuals, regardless of antibody status [<a href="#rid21">21-23</a>].</p><p></p><p class="bulletIndent1">A third dose of MMR vaccine may be useful to limit transmission of mumps in outbreak settings that occur in high-density, close-contact settings, given the possibility of two-dose mumps vaccine failure due to waning of vaccine-induced immunity [<a href="#rid24">24,25</a>]. In one mumps outbreak during which 1755 students (80 percent of students in grades 6 to 12) received a third dose of MMR vaccine, mumps attack rates declined from 4.9 percent (three weeks before vaccination) to 0.13 percent (three weeks after vaccination) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rubella – One dose of vaccine produces a rubella seroconversion rate of about 95 percent. The durability of antibodies produced by the vaccine and by naturally acquired infection is comparable. Titers of antibody induced by vaccine tend to be lower than those produced by natural infection but are protective against infection. Some individuals have been reported to experience symptomatic or asymptomatic infection despite previous immunization [<a href="#rid26">26,27</a>]. Asymptomatic reinfection usually does not lead to detectable viremia [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H12516638"><span class="h1">VACCINE FORMULATIONS</span><span class="headingEndMark"> — </span>Three formulations of measles, mumps, and rubella–containing vaccines are available in the United States, including one formulation that also provides varicella virus coverage [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Measles, mumps, and rubella (MMR) combination vaccine – In November of 2022, the United States Advisory Committee on Immunization Practices (ACIP) expanded the options for MMR vaccines to two options (M-M-R II and PRIORIX), both of which contain genetically similar or identical live attenuated measles, mumps, and rubella viruses [<a href="#rid29">29</a>]. Either vaccine is recommended for routine use in individuals ≥12 months of age. The two vaccines are interchangeable. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measles, mumps, rubella, and varicella (MMRV) combination vaccine – MMRV is a vaccine that includes live attenuated measles, mumps, rubella, and varicella viruses. It is licensed for use in children 12 months through 12 years of age.</p><p></p><p>These vaccines contain small amounts of <a class="drug drug_general" data-topicid="9686" href="/d/drug information/9686.html" rel="external">neomycin</a>, and the M-M-R II and MMRV vaccines also contain gelatin [<a href="#rid1">1,29</a>]. They are supplied as a lyophilized (freeze-dried) powder with a separate diluent. Proper storage and handling of powder and diluents are necessary to prevent inactivation of the vaccine viruses [<a href="#rid1">1</a>].</p><p>Single-antigen (ie, monovalent) formulations of measles, mumps, and rubella vaccines are not available in the United States [<a href="#rid30">30</a>] but are available in some other countries [<a href="#rid31">31</a>]. An investigational monovalent aerosolized measles vaccine resulted in lower rates of seropositivity than a subcutaneously administered vaccine in a randomized trial in Indian children [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H12517418"><span class="h1">INDICATIONS AND SCHEDULES</span></p><p class="headingAnchor" id="H12517425"><span class="h2">United States</span></p><p class="headingAnchor" id="H8598624"><span class="h3">Who should be immunized</span></p><p class="headingAnchor" id="H1537000227"><span class="h4">Children</span><span class="headingEndMark"> — </span>In the United States, routine immunization with measles, mumps, and rubella (MMR) vaccine is recommended for children at 12 to 15 months and 4 through 6 years of age [<a href="#rid1">1,33</a>]. The second dose of MMR can be given as early as 28 days after the first dose, provided that both doses are given at ≥12 months of age [<a href="#rid1">1,33</a>]. In several studies, the median seroconversion rates for measles, mumps, and rubella after one dose of MMR were ≥94 percent; immunity appears to be long-lasting  (<a class="graphic graphic_table graphicRef64771" href="/d/graphic/64771.html" rel="external">table 1</a>) [<a href="#rid9">9,10,34-41</a>].</p><p>Further details on MMR immunization in children are found elsewhere. (See  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents"</a>.)</p><p class="headingAnchor" id="H2241123411"><span class="h4">Adults</span></p><p class="headingAnchor" id="H3919179282"><span class="h5">General principles</span><span class="headingEndMark"> — </span>In general, immunity to measles and mumps may be presumed for adults born before 1957; health care workers are an exception (see <a class="local">'Health care workers'</a> below). In contrast, immunity to rubella is not assured and should be determined by laboratory testing for all women of childbearing age, regardless of birth year. (See  <a class="medical medical_review" href="/d/html/446.html" rel="external">"Prenatal care: Initial assessment", section on 'Documentation of rubella immunity'</a>.)</p><p>At least one dose of MMR vaccine should be administered to adults born in 1957 or later (who are not included in the categories below), unless there is laboratory evidence of immunity to each of the three viruses (or a medical contraindication to vaccination) [<a href="#rid42">42</a>]. Since it may be difficult to obtain childhood immunization records, a practical strategy endorsed by the American College of Physicians is to immunize all adults born after 1956 [<a href="#rid43">43</a>]. There is no increase in vaccine-associated adverse reactions in people who are already immune to measles, mumps, and/or rubella [<a href="#rid3">3</a>].</p><p>For individuals in the following categories, formal documentation of immunity should be established [<a href="#rid1">1</a>]; in the absence of evidence for immunity, two doses of the MMR vaccine should be administered at least 28 days apart  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 2</a>) (see <a class="local">'Documenting immunity'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Formal documentation of immunity to <strong>measles</strong>, <strong>mumps</strong>, and <strong>rubella</strong> should be established for adults in the following categories:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Students in post-secondary educational institutions</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Health care workers (see <a class="local">'Health care workers'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>International travelers</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HIV-infected individuals who do not have current evidence of severe immunocompromise (defined as CD4+ T lymphocyte [CD4] percentage &lt;15 percent or CD4 count &lt;200 cells/microL) (see  <a class="medical medical_review" href="/d/html/3706.html" rel="external">"Immunizations in persons with HIV", section on 'Measles, mumps, and rubella vaccine'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hematopoietic cell transplant (HCT) recipients 24 months following HCT who are no longer receiving immunosuppression and do not have active graft-versus-host disease [<a href="#rid44">44</a>] (see  <a class="medical medical_review" href="/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients", section on 'Measles, mumps, and rubella'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Formal documentation of immunity to <strong>measles</strong> should be established for:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals at risk for exposure during an outbreak (see <a class="local">'Outbreak settings'</a> below and  <a class="medical medical_review" href="/d/html/3019.html" rel="external">"Measles: Epidemiology and transmission", section on 'Transmission'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals previously vaccinated with attenuated measles vaccine accompanied by <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> or high-titer immune globulin</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals previously vaccinated with killed measles vaccine or vaccine of unknown type between 1963 and 1967</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Close contacts of immunocompromised individuals</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Formal documentation of immunity to <strong>mumps</strong> should be established for individuals previously vaccinated with killed mumps vaccine or mumps vaccine of an unknown type.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Formal documentation of immunity to <strong>rubella</strong> should be established for all women of childbearing age via laboratory testing. If there is no evidence of immunity, women who are not pregnant should be vaccinated. Pregnant women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the health care facility. Repeat testing for serologic evidence of immunity thereafter is not required.</p><p></p><p class="headingAnchor" id="H1061291950"><span class="h5">Health care workers</span><span class="headingEndMark"> — </span>Formal documentation of immunity to measles, mumps, and rubella should be established for health care workers (even those born before 1957) [<a href="#rid45">45,46</a>].</p><p>For health care workers who have no laboratory evidence of immunity to measles or mumps (or laboratory confirmation of disease), two doses of MMR should be given at least four weeks apart. If they only lack laboratory evidence of immunity to rubella, at least one dose of MMR should be given [<a href="#rid47">47</a>]. </p><p>Issues related to post-exposure prophylaxis are discussed below. (See <a class="local">'Post-exposure prophylaxis'</a> below.)</p><p>Health care workers without evidence of immunity who were exposed to an individual with measles should be excluded from the workplace from day 5 through day 21 after exposure. If the case is confirmed, even those who were vaccinated within 72 hours should be excluded [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H8592228"><span class="h3">Documenting immunity</span><span class="headingEndMark"> — </span>Catch-up MMR immunization is necessary for individuals who lack appropriate evidence of immunity or whose MMR immunization status is unknown [<a href="#rid1">1,33</a>]. Evidence of immunity is established by one of the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Documentation of age-appropriate vaccination with a live attenuated vaccine (vaccination reported by a caregiver is not valid without appropriate documentation):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For measles – Two doses of measles-containing vaccine, both administered at ≥12 months of age, separated by ≥28 days (doses administered before 12 months of age are not counted).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For mumps – Two doses of mumps-containing vaccine, both administered at ≥12 months of age, separated by ≥28 days (doses administered before 12 months of age are not counted).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For rubella – One dose of rubella-containing vaccine administered at ≥12 months of age, except for pregnant women who require laboratory evidence of immunity or confirmation of disease.</p><p></p><p class="bulletIndent1">For individuals who have documented receipt of two doses of MMR, the United States Centers for Disease Control and Prevention does not require an antibody titer to be measured for evidence of measles immunity. Fewer than 1 percent of immunocompetent individuals lack laboratory evidence of immunity after two doses of MMR, although antibody titers may wane over time [<a href="#rid13">13</a>]. (See <a class="local">'Vaccine efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory evidence of immunity (measles, mumps, and rubella immunoglobulin [Ig]G). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory confirmation of measles, mumps, and rubella disease (clinical diagnosis without laboratory confirmation is not sufficient evidence of immunity). (See  <a class="medical medical_review" href="/d/html/3021.html" rel="external">"Measles: Clinical manifestations, diagnosis, treatment, and prevention", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/8310.html" rel="external">"Mumps", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/8301.html" rel="external">"Rubella", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Birth before 1957 – Individuals born before 1957 are generally considered immune to measles and mumps, except health care workers. (See <a class="local">'Health care workers'</a> above.) </p><p></p><p class="headingAnchor" id="H12518363"><span class="h3">Outbreak settings</span><span class="headingEndMark"> — </span>Outbreak settings should be managed as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In a <strong>measles</strong> outbreak setting, adults who are incompletely immunized against measles should receive two doses of MMR separated by at least 28 days; the initial vaccination should be administered within 72 hours of exposure [<a href="#rid1">1</a>]. This includes unvaccinated health care workers born before 1957 with no laboratory evidence of measles and mumps immunity (or confirmation of disease). (See <a class="local">'Health care workers'</a> above and  <a class="medical medical_review" href="/d/html/3019.html" rel="external">"Measles: Epidemiology and transmission", section on 'Outbreak control measures'</a>.)</p><p></p><p class="bulletIndent1">Individuals unable to produce documentation of measles immunity should be excluded from the outbreak setting until they have complied with vaccination requirements. Those who are exempt from vaccination for medical, religious, or other reasons should be excluded from the outbreak setting for a minimum of three weeks after the onset of rash in the last measles case.</p><p></p><p class="bulletIndent1">Recommendations for children in an outbreak setting are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'International travel and outbreaks'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a <strong>mumps</strong> outbreak setting, individuals who are incompletely immunized against mumps should receive two doses of MMR separated by at least 28 days [<a href="#rid1">1</a>]. Individuals who have been previously vaccinated with two doses of MMR vaccine should receive a third dose of mumps virus-containing vaccine [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/8310.html" rel="external">"Mumps", section on 'Outbreak settings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a <strong>rubella</strong> outbreak setting, individuals who are incompletely immunized against rubella should receive two doses of MMR separated by at least 28 days [<a href="#rid1">1</a>]. </p><p></p><p>Administration of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> should not be used for outbreak control [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H12518653"><span class="h3">Post-exposure prophylaxis</span><span class="headingEndMark"> — </span>Following <strong>measles</strong> exposure, post-exposure prophylaxis for susceptible individuals consists of MMR vaccination within 72 hours of exposure (in the absence of a contraindication) [<a href="#rid1">1,50</a>]. Administration of vaccine is preferable to administration of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> since vaccination provides active, long-lasting immunity against measles [<a href="#rid51">51</a>].</p><p><a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">Immune globulin</a> can prevent or diminish the severity of measles if administered to nonimmune individuals within six days of exposure [<a href="#rid3">3,52</a>]. Immune globulin is not indicated for individuals who have received one dose of measles-containing vaccine at age ≥12 months in the absence of immunosuppression. Administration of immune globulin is appropriate for exposed individuals with increased risk of measles complications with contraindication for MMR vaccination as follows [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant women without evidence of immunity – Pregnant women may be at increased risk for severe measles and complications. Therefore, administration of intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG; 400 mg/kg) is appropriate for pregnant women without evidence of measles immunity who have been exposed to measles.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised patients – Severely immunocompromised patients exposed to measles should receive post-exposure prophylaxis with <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> (400 mg/kg) regardless of immunologic or vaccination status. Such patients include individuals with severe immunodeficiency, bone marrow transplant recipients until at least 12 months after completing all immunosuppressive treatment (or longer in patients with graft-versus-host disease), patients on treatment for acute lymphoblastic leukemia until at least six months after completion of immunosuppressive chemotherapy, patients with HIV infection and CD4 percentage &lt;15 percent (all ages) or CD4 count &lt;200 cells/mm³ (age &gt;5 years), and patients who have not received MMR vaccine since receiving effective antiretroviral therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recommendations for use of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> in children, including infants, exposed to measles are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Measles postexposure prophylaxis'</a>.)</p><p></p><p>Nonimmune individuals with measles exposure who received <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> should subsequently receive MMR vaccine (no earlier than six months after intramuscular immune globulin or eight months after IVIG), provided MMR vaccine is not otherwise contraindicated. (See <a class="local">'Precautions'</a> below.)</p><p>Following <strong>mumps</strong> or <strong>rubella</strong> exposure, neither post-exposure MMR nor <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> has been shown to prevent disease or lessen disease severity in the absence of an outbreak [<a href="#rid1">1</a>]. (See <a class="local">'Outbreak settings'</a> above.)</p><p class="headingAnchor" id="H8592355"><span class="h3">International travel</span><span class="headingEndMark"> — </span>Before international travel, individuals who are incompletely immunized against measles should receive two doses of MMR separated by at least 28 days, with the first dose administered on or after the first birthday. Recommendations for children, including infants, are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Measles, mumps, and rubella'</a> and  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'International travel and outbreaks'</a>.)</p><p class="headingAnchor" id="H12518927"><span class="h2">Other countries</span><span class="headingEndMark"> — </span>Routine immunization schedules vary among countries. Schedules for individual countries are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=3893" target="_blank">World Health Organization</a>.</p><p class="headingAnchor" id="H12519327"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>MMR and MMRV vaccines should NOT be administered to individuals who have certain conditions  (<a class="graphic graphic_table graphicRef101585" href="/d/graphic/101585.html" rel="external">table 2</a>) [<a href="#rid1">1,42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe allergic reaction (eg, anaphylaxis) after a previous dose of MMR or to a vaccine component (eg, <a class="drug drug_general" data-topicid="9686" href="/d/drug information/9686.html" rel="external">neomycin</a>, gelatin). (See  <a class="medical medical_review" href="/d/html/2074.html" rel="external">"Allergic reactions to vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy or attempting to become pregnant – Women should be counseled to avoid becoming pregnant for 28 days after receiving MMR because of the theoretic risk of congenital rubella syndrome [<a href="#rid1">1</a>]. Pregnant women without immunity to measles, mumps, and rubella should receive a dose of MMR postpartum. (See  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy"</a> and  <a class="medical medical_review" href="/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Measles, mumps, rubella'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunodeficiency – Individuals with immunodeficiency are at risk for severe complications following immunization with live attenuated virus vaccines (eg, encephalitis, pneumonitis) [<a href="#rid1">1,53-58</a>]. Immune deficiencies that are contraindications to MMR include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary or acquired immunodeficiency (eg, cellular immunodeficiency, hypogammaglobulinemia, HIV infection with CD4+ T lymphocyte [CD4] &lt;200 cells/microL or percentage &lt;15 percent). (See  <a class="medical medical_review" href="/d/html/3706.html" rel="external">"Immunizations in persons with HIV", section on 'Measles, mumps, and rubella vaccine'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hematologic or solid tumor malignancy. (See  <a class="medical medical_review" href="/d/html/3899.html" rel="external">"Immunizations in adults with cancer"</a> and  <a class="medical medical_review" href="/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Long-term immunosuppressive therapy, including chemotherapy for malignancy, immunosuppression for transplant recipients, or large daily doses of corticosteroids (equivalent to ≥20 mg per day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) for ≥2 weeks [<a href="#rid59">59</a>]; MMR should be avoided for at least one month after high-dose corticosteroid therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of congenital or hereditary immunodeficiency in a parent or sibling, unless the immune competence of the potential vaccine recipient has been substantiated clinically or verified by a laboratory. </p><p></p><p>Close contacts of patients with contraindications to MMR should receive routine vaccination; secondary transmission associated with MMR vaccination has not been reported [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H3965750241"><span class="h1">PRECAUTIONS</span><span class="headingEndMark"> — </span>When a precaution is present, the decision regarding vaccination should depend upon whether the benefit of protection from the vaccine outweighs the risk of an adverse reaction. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concurrent illness</strong> – Whether measles, mumps, and rubella (MMR) should be administered to individuals with current illness depends upon the severity of the illness. MMR can be safely administered to individuals with mild illness, with or without fever (eg, upper respiratory infection, otitis media, gastroenteritis); seroconversion is not affected by mild illness [<a href="#rid61">61-63</a>]. It is appropriate to delay administration of MMR in the setting of moderate to severe illness, unless the vaccine is being administered for measles exposure. (See <a class="local">'Post-exposure prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recent receipt of blood or </strong><a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> – Receipt of immune globulin or antibody-containing blood products can blunt or block the host response to certain live virus vaccines. The suggested interval between receipt of immune globulin or antibody-containing blood products and administration of MMR varies depending upon the product  (<a class="graphic graphic_table graphicRef72640" href="/d/graphic/72640.html" rel="external">table 3</a>) [<a href="#rid46">46,59,64</a>].</p><p></p><p class="bulletIndent1">Postpartum administration of MMR to women who received anti-D (Rho) <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> or blood products during the last trimester of pregnancy or at delivery is discussed separately. (See  <a class="medical medical_review" href="/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Postpartum immunization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History of thrombocytopenia</strong> – Individuals with a history of thrombocytopenia or thrombocytopenic purpura may have an increased risk of clinically significant thrombocytopenia following immunization with MMR [<a href="#rid1">1</a>]. Decisions regarding administration of the <strong>first</strong> dose MMR to individuals with a history of thrombocytopenia are made on a case-by-case basis contingent upon the assessment of risks and benefits. In many cases, the benefits outweigh the risks.</p><p></p><p class="bulletIndent1">Factors to be considered in the decision include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrence of thrombocytopenia following MMR in individuals with a history thrombocytopenia (both vaccine-associated and nonvaccine-associated) has been reported [<a href="#rid65">65-68</a>], but the magnitude of the risk is unknown.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The likelihood of exposure to MMR (eg, plans for international travel, level of MMR vaccination coverage in the community, etc).</p><p></p><p class="bulletIndent1">Serologic testing can be performed to determine whether the <strong>second</strong> dose of MMR is necessary. Individuals with protective levels of antibody to MMR do not need to receive the second dose. For individuals with history of thrombocytopenia who lack protective levels of antibody to MMR, decisions regarding administration of the second dose of MMR are made on a case-by-case basis based upon the assessment of risks and benefits.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberculosis testing</strong> – MMR may temporarily reduce <a class="drug drug_general" data-topicid="10029" href="/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) sensitivity [<a href="#rid69">69</a>]. The effect of MMR vaccination on interferon-gamma release assay (IGRA) is uncertain [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">If TST or IGRA is warranted for evaluation of tuberculosis, they should be performed before, at the same visit as, or four to six weeks after MMR vaccination [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a> and  <a class="medical medical_review" href="/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History of seizure</strong> – Individuals with a personal or family history of seizures have an increased risk of febrile seizures following MMR, although this does not outweigh the benefits of immunization with MMR or MMRV [<a href="#rid70">70,71</a>]; the risk of seizures in children was estimated at one additional seizure per 2300 doses of MMRV versus MMR [<a href="#rid72">72</a>]. It is not known whether adults with a personal or family history of seizures have a similar risk. (See <a class="local">'Adverse effects'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concurrent use of antivirals</strong> – MMR vaccine can be administered to patients on antivirals. However, for patients receiving MMRV vaccine, antiviral drugs with activity against herpes viruses (eg, <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>) may interfere with the varicella component of the vaccine; for these patients, the antiviral should be discontinued ≥24 hours before administration of the MMRV vaccine and avoided for 14 days after vaccination.</p><p></p><p class="headingAnchor" id="H8595141"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Adverse reactions to measles, mumps, and rubella (MMR) include fever, rash, lymphadenopathy, joint complaints, hypersensitivity reactions, development of immune thrombocytopenia (ITP), and seizures. These reactions occur more frequently with the first than with the second dose [<a href="#rid73">73</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Fever – Fever (&gt;39.4ºC) develops in 5 to 15 percent of MMR recipients, usually within 6 to 12 days after immunization [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rash – Transient rashes also occur in approximately 5 percent of MMR recipients [<a href="#rid46">46</a>]. The combination of fever and rash after MMR immunization generally is attributed to measles vaccine virus but may be due to wild-type measles or other viral illnesses [<a href="#rid74">74</a>]; virologic studies may be warranted in individuals with potential exposure to wild-type measles (eg, international travel, contact with immigrants).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphadenopathy – Transient lymphadenopathy occurs in 5 percent of children and 20 percent of adults [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Joint manifestations – Joint manifestations secondary to the rubella component of the vaccine may occur 7 to 21 days after MMR immunization [<a href="#rid46">46</a>]. Arthralgia occurs in 25 percent of adults, and 10 percent develop arthritis [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypersensitivity reaction – Hypersensitivity reactions to the MMR are usually minor (wheal and flare or urticaria) and have been attributed to trace amounts of <a class="drug drug_general" data-topicid="9686" href="/d/drug information/9686.html" rel="external">neomycin</a> or gelatin but not to egg antigens since MMR does not contain significant amounts of egg-white cross-reacting proteins [<a href="#rid46">46,75,76</a>]. (See  <a class="medical medical_review" href="/d/html/2074.html" rel="external">"Allergic reactions to vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia – Thrombocytopenia has been observed in prospective studies (1 case in 25,000 to 40,000 vaccine doses) [<a href="#rid3">3</a>]. In general, it is transient and occurs within two months of the receipt of vaccine, most commonly at two to three weeks. The risk may be higher in individuals who experienced thrombocytopenia following previous vaccination with MMR. (See <a class="local">'Precautions'</a> above and  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Febrile seizure – The incidence of vaccine-associated seizures has been estimated to be 1 in 3000 MMR doses [<a href="#rid3">3</a>] but is increased in individuals with a history of seizures or with a family history in first-degree relatives. Most are simple febrile seizures and in most cases the benefits of vaccination outweigh the risk of seizures. As noted above, in children there was an estimated one additional febrile seizure in one of every 2300 doses of MMRV versus MMR [<a href="#rid72">72</a>]. (See <a class="local">'Precautions'</a> above and  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MMR does not appear to be associated with encephalopathy. In a retrospective case-control study including 452 children with encephalopathy and related conditions and up to three controls for each case, cases were no more likely than controls to have received MMR during the 90 days before onset of encephalopathy [<a href="#rid77">77</a>].</p><p></p><p class="headingAnchor" id="H4031398"><span class="h1">ADMINISTRATION</span><span class="headingEndMark"> — </span>Measles, mumps, and rubella (MMR) combination vaccine are supplied as a lyophilized (freeze-dried) powder with a separate diluent. Only the diluent that is supplied with the vaccine should be used to reconstitute it; any dose of vaccine that is reconstituted with the incorrect diluent should be repeated.</p><p>The dose of MMR is 0.5 mL [<a href="#rid59">59</a>]. All formulations of MMR can be administered subcutaneously with a 5/8 inch (1.6 cm), 23-to 25-gauge needle [<a href="#rid78">78,79</a>]. The site of subcutaneous administration of individuals &gt;12 months of age is usually the upper outer triceps. Immunogenicity appears to be similar with intramuscular and subcutaneous administration, and some formulations have also been approved for administration via the intramuscular route; refer to local product information for guidance [<a href="#rid78">78-80</a>]. If a formulation intended for subcutaneous use is administered intramuscularly, the dose need not be repeated.</p><p>MMR may be administered at the same clinic visit as other immunizations [<a href="#rid81">81</a>]. However, if live attenuated vaccines (eg, MMR, varicella, live attenuated influenza, yellow fever) are not administered at the same clinic visit, they should be separated by ≥28 days [<a href="#rid59">59</a>]. Administration at &lt;28 days may impair the immune response to one of the vaccines [<a href="#rid82">82-84</a>].</p><p class="headingAnchor" id="H8591915"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H8594616"><span class="h2">HIV infection</span><span class="headingEndMark"> — </span>As stated above, MMR vaccination is contraindicated for individuals with HIV infection and severe immunocompromise (CD4+ T lymphocyte [CD4] percentage &lt;15 percent or CD4 count &lt;200 cells/microL). (See <a class="local">'Contraindications'</a> above.)</p><p>MMR vaccination is warranted for individuals with HIV infection in the absence of severe immunocompromise and no evidence of immunity for measles, mumps, and rubella; such individuals should be immunized with two doses of MMR vaccine, given at least 28 days apart [<a href="#rid1">1,53</a>]. (See <a class="local">'Documenting immunity'</a> above and  <a class="medical medical_review" href="/d/html/3706.html" rel="external">"Immunizations in persons with HIV", section on 'Measles, mumps, and rubella vaccine'</a>.)</p><p class="headingAnchor" id="H8594712"><span class="h2">Contact with immunocompromised hosts</span><span class="headingEndMark"> — </span>MMR can be given to individuals with immunocompromised household contacts, who are at increased risk for severe complications from natural measles infection [<a href="#rid53">53,59</a>]. A 2007 review found no evidence of secondary transmission of measles, mumps, or rubella vaccine viruses from healthy vaccinees caring for or living with immunocompromised contacts [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H8595793"><span class="h2">History of measles, mumps, or rubella infection</span><span class="headingEndMark"> — </span>Individuals with clinical history of measles, mumps, or rubella infection that was not laboratory confirmed should be vaccinated as if they have not had infection [<a href="#rid1">1</a>]. Individuals with laboratory confirmation of measles, mumps, or rubella disease are considered to be immune to that particular disease and need not be vaccinated against it. However, individuals generally receive two doses of MMR vaccine regardless because monovalent vaccines for measles, mumps, or rubella are no longer available in the United States.</p><p class="headingAnchor" id="H8594778"><span class="h2">Egg allergy</span><span class="headingEndMark"> — </span>Egg allergy is <strong>not</strong> a contraindication or precaution to MMR; vaccination can be administered to individuals with egg allergy without prior skin testing or special protocols [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/2074.html" rel="external">"Allergic reactions to vaccines", section on 'Measles, mumps, and rubella'</a>.)</p><p class="headingAnchor" id="H8594445"><span class="h2">Immigrants and refugees</span><span class="headingEndMark"> — </span>Issues related to immigrants and refugees are discussed separately. (See  <a class="medical medical_review" href="/d/html/13959.html" rel="external">"Medical care of adult refugees, immigrants, and migrants", section on 'Immunizations'</a>.)</p><p class="headingAnchor" id="H8595867"><span class="h1">LACK OF ASSOCIATION WITH AUTISM</span><span class="headingEndMark"> — </span>Multiple studies have failed to demonstrate any association between measles, mumps, and rubella (MMR) vaccination and autism or other chronic diseases. However, there is an association between congenital rubella syndrome and autism, highlighting a potential role for MMR immunization in the prevention of autism spectrum disorders [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/2861.html" rel="external">"Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor"</a>.)</p><p class="headingAnchor" id="H1419287296"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110427.html" rel="external">"Society guideline links: Immunizations in adults"</a>.)</p><p class="headingAnchor" id="H53647128"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General recommendations for MMR vaccine in adults</strong> – We recommend that adults born in 1957 or later (who are not included in the categories summarized above) should have documentation of at least one dose of measles, mumps, and rubella (MMR) vaccine unless there is laboratory evidence of immunity to each of the three diseases or a medical contraindication to vaccination (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Who should be immunized'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Documenting immunity</strong> – For adults in the categories summarized above, formal documentation of immunity to measles, mumps, and rubella diseases should be established; in the absence of evidence for immunity, we recommend that two doses of the MMR vaccine should be administered at least 28 days apart (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Who should be immunized'</a> above and <a class="local">'Documenting immunity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of immunity</strong> – Evidence of immunity is established by the following (see <a class="local">'Documenting immunity'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Documentation of age-appropriate vaccination with a live attenuated vaccine (vaccination reported by a caregiver is not valid without appropriate documentation):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For measles – Two doses of measles-containing vaccine, both administered at ≥12 months of age, separated by ≥28 days (doses administered before 12 months of age are not counted)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For mumps – Two doses of mumps-containing vaccine, both administered at ≥12 months of age, separated by ≥28 days (doses administered before 12 months of age are not counted)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For rubella – One dose of rubella-containing vaccine administered at ≥12 months of age, except for pregnant women who require laboratory evidence of immunity or confirmation of disease</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory evidence of immunity (measles, mumps, and rubella immunoglobulin [Ig]G).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory confirmation of measles, mumps, and rubella disease (clinical diagnosis without laboratory confirmation is not sufficient evidence of immunity)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Birth before 1957 – Individuals born before 1957 are generally considered immune to measles and mumps (except health care workers). Rubella immunity should be determined by laboratory testing for all women of childbearing age regardless of birth year. (See <a class="local">'Who should be immunized'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical management of exposures</strong> – Post-exposure prophylaxis for susceptible individuals exposed to <strong>measles</strong> consists of MMR vaccination within 72 hours of exposure (in the absence of a contraindication). If more than 72 hours but less than 6 days have elapsed since exposure, intramuscular <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> may prevent or modify measles infection in nonimmune individuals with increased risk of measles complications (including pregnant women without evidence of immunity and immunocompromised patients).</p><p></p><p class="bulletIndent1">Following <strong>mumps or rubella</strong> exposure, neither post-exposure MMR nor <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> has been shown to prevent disease or lessen disease severity. (See <a class="local">'Post-exposure prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – Contraindications to MMR vaccine include severe allergic reaction after a previous dose or to a vaccine component (eg, gelatin, <a class="drug drug_general" data-topicid="9686" href="/d/drug information/9686.html" rel="external">neomycin</a>), pregnancy, and immunodeficiency  (<a class="graphic graphic_table graphicRef101585" href="/d/graphic/101585.html" rel="external">table 2</a>). (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for altered schedule of vaccination</strong> – Circumstances that may affect the timing of MMR immunization include receipt of blood products or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> within the past 11 months, history of thrombocytopenia or thrombocytopenic purpura, need for tuberculosis testing, concurrent illness, and HIV infection  (<a class="graphic graphic_table graphicRef101585" href="/d/graphic/101585.html" rel="external">table 2</a>). (See <a class="local">'Special populations'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</a></li><li><a class="nounderline abstract_t">Bester JC. Measles and Measles Vaccination: A Review. JAMA Pediatr 2016; 170:1209.</a></li><li><a class="nounderline abstract_t">Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.</a></li><li><a class="nounderline abstract_t">Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev 2012; :CD004407.</a></li><li><a class="nounderline abstract_t">Fowlkes A, Witte D, Beeler J, et al. Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi. J Infect Dis 2011; 204 Suppl 1:S149.</a></li><li><a class="nounderline abstract_t">Watson JC, Pearson JA, Markowitz LE, et al. An evaluation of measles revaccination among school-entry-aged children. Pediatrics 1996; 97:613.</a></li><li class="breakAll">Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book), 12th ed, Atkinson W, Wolfe C, Hamborsky J (Eds), The Public Health Foundation, Washington, DC 2011.</li><li><a class="nounderline abstract_t">Fiebelkorn AP, Coleman LA, Belongia EA, et al. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults. J Infect Dis 2016; 213:1115.</a></li><li><a class="nounderline abstract_t">LeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007; 161:294.</a></li><li><a class="nounderline abstract_t">Davidkin I, Jokinen S, Broman M, et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008; 197:950.</a></li><li><a class="nounderline abstract_t">Mossong J, O'Callaghan CJ, Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine 2000; 19:523.</a></li><li><a class="nounderline abstract_t">Bolotin S, Osman S, Hughes SL, et al. In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis. J Infect Dis 2022; 226:1127.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. Measles. https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html (Accessed on May 28, 2019).</li><li><a class="nounderline abstract_t">Cherry JD, Zahn M. Clinical Characteristics of Measles in Previously Vaccinated and Unvaccinated Patients in California. Clin Infect Dis 2018; 67:1315.</a></li><li><a class="nounderline abstract_t">Bitzegeio J, Majowicz S, Matysiak-Klose D, et al. Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity. Euro Surveill 2019; 24.</a></li><li><a class="nounderline abstract_t">Rice P, Young Y, Cohen B, Ramsay M. MMR immunisation after contact with measles virus. Lancet 2004; 363:569.</a></li><li><a class="nounderline abstract_t">King GE, Markowitz LE, Patriarca PA, Dales LG. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J 1991; 10:883.</a></li><li><a class="nounderline abstract_t">Barrabeig I, Rovira A, Rius C, et al. Effectiveness of measles vaccination for control of exposed children. Pediatr Infect Dis J 2011; 30:78.</a></li><li><a class="nounderline abstract_t">Ma SJ, Li X, Xiong YQ, et al. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety. Medicine (Baltimore) 2015; 94:e1721.</a></li><li><a class="nounderline abstract_t">Jokinen S, Osterlund P, Julkunen I, Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J Infect Dis 2007; 196:861.</a></li><li><a class="nounderline abstract_t">Hanna-Wakim R, Yasukawa LL, Sung P, et al. Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis 2008; 197:1669.</a></li><li><a class="nounderline abstract_t">Vandermeulen C, Clement F, Roelants M, et al. Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination. J Infect Dis 2009; 199:1457.</a></li><li><a class="nounderline abstract_t">Ong G, Goh KT, Ma S, Chew SK. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect 2005; 51:294.</a></li><li><a class="nounderline abstract_t">Albertson JP, Clegg WJ, Reid HD, et al. Mumps Outbreak at a University and Recommendation for a Third Dose of Measles-Mumps-Rubella Vaccine - Illinois, 2015-2016. MMWR Morb Mortal Wkly Rep 2016; 65:731.</a></li><li><a class="nounderline abstract_t">Ogbuanu IU, Kutty PK, Hudson JM, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics 2012; 130:e1567.</a></li><li><a class="nounderline abstract_t">Braun C, Kampa D, Fressle R, et al. Congenital rubella syndrome despite repeated vaccination of the mother: a coincidence of vaccine failure with failure to vaccinate. Acta Paediatr 1994; 83:674.</a></li><li><a class="nounderline abstract_t">Parkman PD. Making vaccination policy: the experience with rubella. Clin Infect Dis 1999; 28 Suppl 2:S140.</a></li><li class="breakAll">Best JM, Icenogle JP, Brown DWG. Rubella. In: Principles and Practices of Clinical Virology, 6th Ed, Zuckerman AJ, Banatvala JE, Schoub BD, et al (Eds), John Wiley &amp; Sons, Ltd, West Sussex, UK 2009. p.561.</li><li><a class="nounderline abstract_t">Krow-Lucal E, Marin M, Shepersky L, et al. Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1465.</a></li><li><a class="nounderline abstract_t">Kimberlin DW, Bocchini JA. Monovalent vaccines no longer available for measles, mumps, rubella. AAP News 2009; 30:9.</a></li><li class="breakAll">Unicef. Measles Monovalent and Meales and Rubella Combination Vaccines: Supply and Demand Update. https://www.unicef.org/supply/media/821/file/measles%20containing%20vaccines%20MCVs%20supply%20and%20demand%20update.pdf (Accessed on November 01, 2021).</li><li><a class="nounderline abstract_t">Low N, Bavdekar A, Jeyaseelan L, et al. A randomized, controlled trial of an aerosolized vaccine against measles. N Engl J Med 2015; 372:1519.</a></li><li><a class="nounderline abstract_t">Wodi AP, Murthy N, Bernstein H, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:234.</a></li><li><a class="nounderline abstract_t">Markowitz LE, Albrecht P, Orenstein WA, et al. Persistence of measles antibody after revaccination. J Infect Dis 1992; 166:205.</a></li><li><a class="nounderline abstract_t">Ward BJ, Boulianne N, Ratnam S, et al. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995; 172:1591.</a></li><li><a class="nounderline abstract_t">LeBaron CW, Forghani B, Matter L, et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 200:888.</a></li><li><a class="nounderline abstract_t">Hillary IB, Griffith AH. Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. Vaccine 1984; 2:274.</a></li><li><a class="nounderline abstract_t">Christenson B, Böttiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine 1994; 12:41.</a></li><li><a class="nounderline abstract_t">LeBaron CW, Forghani B, Beck C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 199:552.</a></li><li><a class="nounderline abstract_t">Gothefors L, Bergström E, Backman M. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis 2001; 33:545.</a></li><li><a class="nounderline abstract_t">Broliden K, Abreu ER, Arneborn M, Böttiger M. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme. Vaccine 1998; 16:323.</a></li><li><a class="nounderline abstract_t">Murthy N, Wodi AP, Bernstein H, et al. Recommended Adult Immunization Schedule, United States, 2022. Ann Intern Med 2022; 175:432.</a></li><li class="breakAll">American College Physicians Task Force on Adult Immunization and Infectious Diseases Society of America. Guide for adult immunization. Philadelphia. American College of Physicians, 1994.</li><li><a class="nounderline abstract_t">Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Recommendations and Reports. https://www.cdc.gov/mmwr/pdf/rr/rr6007.pdf (Accessed on November 01, 2021).</li><li class="breakAll">American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</li><li><a class="nounderline abstract_t">Freedman M, Kroger A, Hunter P, et al. Recommended Adult Immunization Schedule, United States, 2020. Ann Intern Med 2020; 172:337.</a></li><li><a class="nounderline abstract_t">Bolyard EA, Tablan OC, Williams WW, et al. Hospital Infection Control Advisory Committee. Guidelines for infection control in health-care personnel. Am J Infect Control 1998; 26:289.</a></li><li><a class="nounderline abstract_t">Marin M, Marlow M, Moore KL, Patel M. Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. MMWR Morb Mortal Wkly Rep 2018; 67:33.</a></li><li><a class="nounderline abstract_t">Arciuolo RJ, Jablonski RR, Zucker JR, Rosen JB. Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013. Clin Infect Dis 2017; 65:1843.</a></li><li><a class="nounderline abstract_t">Sheppeard V, Forssman B, Ferson MJ, et al. The effectiveness of prophylaxis for measles contacts in NSW. N S W Public Health Bull 2009; 20:81.</a></li><li class="breakAll">Measles: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook - 12th Edition (April 2011) http://www.cdc.gov/vaccines/pubs/pinkbook/meas.html (Accessed on November 15, 2011).</li><li><a class="nounderline abstract_t">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a class="nounderline abstract_t">Poon TP, Tchertkoff V, Win H. Subacute measles encephalitis with AIDS diagnosed by fine needle aspiration biopsy. A case report. Acta Cytol 1998; 42:729.</a></li><li><a class="nounderline abstract_t">Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999; 29:855.</a></li><li><a class="nounderline abstract_t">Baram TZ, Gonzalez-Gomez I, Xie ZD, et al. Subacute sclerosing panencephalitis in an infant: diagnostic role of viral genome analysis. Ann Neurol 1994; 36:103.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 1996; 45:603.</a></li><li><a class="nounderline abstract_t">Derryck A, LaRussa P, Steinberg S, et al. Varicella and zoster in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1998; 17:931.</a></li><li class="breakAll">Centers for Disease Control and Prevention. General best practice guidelines for immunization. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html (Accessed on May 16, 2019).</li><li><a class="nounderline abstract_t">Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.</a></li><li><a class="nounderline abstract_t">King GE, Markowitz LE, Heath J, et al. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. JAMA 1996; 275:704.</a></li><li><a class="nounderline abstract_t">Dennehy PH, Saracen CL, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics 1994; 94:514.</a></li><li><a class="nounderline abstract_t">Ratnam S, West R, Gadag V. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection. J Pediatr 1995; 127:432.</a></li><li><a class="nounderline abstract_t">Siber GR, Werner BG, Halsey NA, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr 1993; 122:204.</a></li><li><a class="nounderline abstract_t">Nieminen U, Peltola H, Syrjälä MT, et al. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr 1993; 82:267.</a></li><li><a class="nounderline abstract_t">Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J 1996; 15:88.</a></li><li><a class="nounderline abstract_t">Drachtman RA, Murphy S, Ettinger LJ. Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pediatr Adolesc Med 1994; 148:326.</a></li><li><a class="nounderline abstract_t">Vlacha V, Forman EN, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics 1996; 97:738.</a></li><li><a class="nounderline abstract_t">Brickman HF, Beaudry PH, Marks MI. The timing of tuberculin tests in relation to immunization with live viral vaccines. Pediatrics 1975; 55:392.</a></li><li><a class="nounderline abstract_t">Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004; 292:351.</a></li><li><a class="nounderline abstract_t">Berg AT, Shinnar S, Shapiro ED, et al. Risk factors for a first febrile seizure: a matched case-control study. Epilepsia 1995; 36:334.</a></li><li class="breakAll">MMRV Vaccine and Febrile Seizures. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/vaccinesafety/vaccines/mmrv/mmrv-febrile-seizures.html. (Accessed on July 03, 2022).</li><li><a class="nounderline abstract_t">LeBaron CW, Bi D, Sullivan BJ, et al. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. Pediatrics 2006; 118:1422.</a></li><li><a class="nounderline abstract_t">Ting CY, Tee NW, Thoon KC. Could a fever and rash after the measles, mumps and rubella vaccination indicate wild-type measles? Acta Paediatr 2015; 104:e232.</a></li><li><a class="nounderline abstract_t">James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332:1262.</a></li><li><a class="nounderline abstract_t">Beck SA, Williams LW, Shirrell MA, Burks AW. Egg hypersensitivity and measles-mumps-rubella vaccine administration. Pediatrics 1991; 88:913.</a></li><li><a class="nounderline abstract_t">Ray P, Hayward J, Michelson D, et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J 2006; 25:768.</a></li><li class="breakAll">M-M-R II (measles, mumps, and rubella virus vaccine live). US Food and Drug Administration approved product information. Revised February, 2023. Available online at: https://www.fda.gov/media/75191/download (Accessed on March 01, 2023).</li><li class="breakAll">ProQuad (measles, mumps, rubella, and varicella vaccine live). US Food and Drug Administration approved product information. Revised March, 2023. https://www.fda.gov/media/147563/download (Accessed on March 01, 2023).</li><li><a class="nounderline abstract_t">Knuf M, Zepp F, Meyer CU, et al. Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. Eur J Pediatr 2010; 169:925.</a></li><li><a class="nounderline abstract_t">Cassidy WM, Jones G, Williams K, et al. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. J Adolesc Health 2005; 36:187.</a></li><li><a class="nounderline abstract_t">PETRALLI JK, MERIGAN TC, WILBUR JR. ACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDREN. Lancet 1965; 2:401.</a></li><li><a class="nounderline abstract_t">PETRALLI JK, MERIGAN TC, WILBUR JR. CIRCULATING INTERFERON AFTER MEASLES VACCINATION. N Engl J Med 1965; 273:198.</a></li><li><a class="nounderline abstract_t">Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 2003; 112:e98.</a></li><li><a class="nounderline abstract_t">Chess S, Fernandez P, Korn S. Behavioral consequences of congenital rubella. J Pediatr 1978; 93:699.</a></li></ol></div><div id="topicVersionRevision">Topic 3893 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23760231" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27695849" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Measles and Measles Vaccination: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9639369" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336803" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vaccines for measles, mumps and rubella in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21666156" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628596" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : An evaluation of measles revaccination among school-entry-aged children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628596" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : An evaluation of measles revaccination among school-entry-aged children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26597262" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17339511" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419470" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11027817" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35417025" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35417025" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29878209" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical Characteristics of Measles in Previously Vaccinated and Unvaccinated Patients in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31039834" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14975626" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : MMR immunisation after contact with measles virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1766702" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical efficacy of measles vaccine during the 1990 measles epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844460" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effectiveness of measles vaccination for control of exposed children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26554769" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17703416" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419345" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immune responses to mumps vaccine in adults who were vaccinated in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19320590" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291282" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467572" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mumps Outbreak at a University and Recommendation for a Third Dose of Measles-Mumps-Rubella Vaccine - Illinois, 2015-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129075" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7919771" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Congenital rubella syndrome despite repeated vaccination of the mother: a coincidence of vaccine failure with failure to vaccinate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10447033" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Making vaccination policy: the experience with rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10447033" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Making vaccination policy: the experience with rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36395065" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Monovalent vaccines no longer available for measles, mumps, rubella</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Monovalent vaccines no longer available for measles, mumps, rubella</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25875257" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomized, controlled trial of an aerosolized vaccine against measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35176011" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1607699" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Persistence of measles antibody after revaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7594723" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659440" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6531967" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8303939" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19113988" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11515768" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9607050" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175828" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recommended Adult Immunization Schedule, United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175828" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Recommended Adult Immunization Schedule, United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19747629" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19747629" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19747629" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016359" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Recommended Adult Immunization Schedule, United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hospital Infection Control Advisory Committee. Guidelines for infection control in health-care personnel</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29324728" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29028959" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19552854" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The effectiveness of prophylaxis for measles contacts in NSW.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19552854" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The effectiveness of prophylaxis for measles contacts in NSW.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9622696" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Subacute measles encephalitis with AIDS diagnosed by fine needle aspiration biopsy. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589903" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Measles inclusion-body encephalitis caused by the vaccine strain of measles virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8024248" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Subacute sclerosing panencephalitis in an infant: diagnostic role of viral genome analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8676852" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9802645" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Varicella and zoster in children with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9802645" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Varicella and zoster in children with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17520544" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8594268" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936862" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7658276" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8429432" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Interference of immune globulin with measles and rubella immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8495082" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8684885" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8130872" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628619" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1143978" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The timing of tuberculin tests in relation to immunization with live viral vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265850" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7541745" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Risk factors for a first febrile seizure: a matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7541745" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Risk factors for a first febrile seizure: a matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17015532" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25646657" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Could a fever and rash after the measles, mumps and rubella vaccination indicate wild-type measles?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7708070" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Safe administration of the measles vaccine to children allergic to eggs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1945631" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Egg hypersensitivity and measles-mumps-rubella vaccine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940831" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940831" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940831" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20148263" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15737773" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14346758" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : ACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDREN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14306336" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : CIRCULATING INTERFERON AFTER MEASLES VACCINATION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897314" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/702254" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Behavioral consequences of congenital rubella.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
